Onconova Therapeutics Inc Stock Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Sales 2024 * | 210K 287K | Sales 2025 * | 300K 409K | Capitalization | 13.61M 18.57M |
---|---|---|---|---|---|
Net income 2024 * | -23M -31.38M | Net income 2025 * | -28M -38.2M | EV / Sales 2024 * | 64.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 45.4 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
1st Jan change | Capi. | |
---|---|---|
+30.01% | 48.16B | |
-0.75% | 41.73B | |
+43.17% | 41.03B | |
-5.31% | 28.77B | |
+10.22% | 25.59B | |
-21.06% | 18.96B | |
+7.42% | 12.92B | |
+26.92% | 12.03B | |
-3.10% | 11.77B |